Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 118, Issue 2, Pages 326-334Publisher
WILEY
DOI: 10.1002/ijc.21373
Keywords
colon cancer; FLIP; PKC6; NF-kappa B; signal transduction
Categories
Funding
- NIDDK NIH HHS [P01 DK035608, P01 DK35608, R01 DK48498, R01 DK048498, P01 DK035608-19A10001] Funding Source: Medline
Ask authors/readers for more resources
FLICE-like inhibitory protein (FLIP), a naturally occurring caspase-inhibitory protein that lacks the critical cysteine domain necessary for catalytic activity, is a negative regulator of Fas-induced apoptosis. Decreased FLIP levels sensitize tumor cells to Fas- and TRAIL-mediated apoptosis; however, the cellular mechanisms regulating FLIP expression have not been defined. Here, we examined the roles of the PKC and NF-kappa B pathway in the regulation of FLIP in human colon cancers. FLIP mRNA levels were increased in Caco-2 cells by treatment with PMA; actinomycin D completely inhibited the induction of FLIP by PMA, indicating transcriptional regulation. PKC inhibitors Go6983 and Ro-31-8220 blocked PMA-stimulated FLIP expression. Pretreatment with the PKC delta-selective inhibitor rottlerin or transfection with PKC delta siRNA inhibited PMA-induced FLIP expression, which identifies a role for PKC delta in FLIP induction. Treatment with the proteasome inhibitor, MG132, or the NF-kappa B inhibitor (e.g., PDTC and gliotoxin), or overexpression of the superrepressor of I kappa B-alpha inhibited PMA-induced upregulation of FLIP. Moreover, PMA-induced NF-kappa B transactivation was blocked by GF109203x. In conclusion, our results demonstrate a critical role for PKC delta/NF-kappa B in the regulation of FLIP in human colon cancer cells. (c) 2005 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available